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INTRODUCTION
Atrial fibrillation (AF) is the most commonly occur-
ring sustained cardiac arrhythmia1. Above age 40 nearly 
1 in 4 people will develop AF2 and the prevalence 
increases with age3. Atrial stasis, endothelial dysfunction 
and increased blood coagulability lead to thrombus for-
mation resulting in a 4- to 5-fold increase in the risk of 
ischaemic stroke relative to the non-affected population4. 
Stroke in AF is generally more severe and  associated with 
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greater mortality and disability as compared to stroke 
from other causes5. Over the years, many strategies have 
been proposed for thromboprophylaxis in AF. Aspirin 
has been used widely for many years but has been proven 
inferior to warfarin and not significantly better than 
placebo for stroke prevention in AF6. Well-controlled 
warfarin therapy is very effective in reducing the risk of 
ischaemic stroke but warfarin has a narrow therapeutic 
window and irregular gastrointestinal absorption with 
many drug and dietary interactions. For this reason, 
achieving good control requires careful monitoring with 
regular dose adjustments. 
Unlike warfarin, the non-vitamin K antagonist oral 
anticoagulants (NOACs) have more predictable phar-
macokinetic profiles, wide therapeutic windows, mini-
mal drug interactions and do not require therapeutic 
monitoring. Several large, international, randomized 
controlled trials have shown the available NOACs to be 
at least as good as or superior to warfarin in the proph-
ylaxis of stroke or systemic embolism (SE) compared to 
warfarin, with similar or lower risk for major bleeding. 
In one trial, the NOAC apixaban was proven superior 
for the prevention of stroke or SE compared to aspirin. 
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stroke or SE, and the rate of major bleeding in patients 
with AF on treatment with NOACs. We used the data 
from the five randomized clinical trials and in addition 
the rate of stroke or SE and the rate of major bleeding in 
one large high-quality registry with independent central 
adjudication of events, reflecting real-life information.
METHODS
We collected the mean CHADS2 score, rate of stroke 
or SE, rate of major bleeding, rate of bleeding from a gas-
trointestinal site and the number of patients with a fatal 
bleeding, when available, from each study (table 1). From 
these data we related the CHADS2 score of each study to 
the rate of stroke or SE and to the rate of major bleeding. 
We also evaluated the results with a high and a low dose of 
the study drug when this was prespecified in the protocols.
We plotted the rate of stoke or SE and the rate of 
major bleeding against the CHADS2 risk score from each 
study (table 1 and table 2). In studies where the results 
of two dose regimens were reported, their different 
impact on outcomes is discussed and the rate of stroke 
or systemic embolism was plotted against the rate of 
major bleeding for each dose (figure 3).
CHADS2 score, the rate of stroke or SE, and major 
bleeding
Dabigatran, a direct thrombin inhibitor, was evalu-
ated in the phase III RE-LY (Randomized Evaluation of 
Long-term-Anticoagulation Therapy) study10. The 
RE-LY study randomized 6,076 patients with AF to a 
treatment with dabigatran 150 mg twice daily (b.i.d.) 
and 6,015 patients to a treatment with dabigatran 110 mg 
b.i.d. The primary efficacy outcome, stroke or SE 
occurred in 1.11%/y of the patients in the 150-mg group, 
Despite the fact that there are no direct head-to-head 
comparisons between the different NOACs and that 
indirect comparison between the different trials is com-
plicated because of baseline differences, inclusion crite-
ria (particularly stroke risk), CHADS2 score and varying 
dose reduction protocols, certain molecules have been 
proposed for subgroups of patients based mainly on the 
perception of different bleeding risks7,8. Recently, impor-
tant information has become available of efficacy and 
bleeding risk with NOACs in routine clinical practice.
OBJECTIVES 
Until now, the results of five large international ran-
domized controlled trials have been reported. In all of 
them the primary efficacy end point was stroke or SE 
and the primary safety outcome the occurrence of major 
bleeding (in one trial the primary safety end point was 
major and non-major clinically relevant bleeding events 
but major bleeding was reported separately). In four of 
these trials, dabigatran, rivaroxaban, apixaban and edo-
baxan were compared to warfarin in a non-inferiority 
protocol. In the fifth trial apixaban was compared to 
aspirin in a superiority protocol. 
In all these trials, the risk of stroke was assessed 
according to the CHADS2 score system, introduced in 
2001 and based upon a cumulative scoring system focus-
ing on five major risk factors: congestive heart failure, 
hypertension, age ≥ 75 years, diabetes, and history of 
stroke or transient ischaemic attack. Each factor is scored 
1, except the cerebral events scored 2 points, reflecting 
their increased weight. The original validation of the 
score classified CHADS2 1-2 as moderate, and CHADS 
> 2 as high risk9. 
The aim of the present report was to highlight the 
relationships between CHADS2 score and the rate of 
Table 1 Thromboembolic and major bleeding events in the studies analysed

























Patients (n) 7,001 7,035 7,034 6,076 6,015 9,120 2,808 6, 784
CHADS2 3.5 2.8 2.8 2.2 2.1 2.1 2 2
Stroke and SE (%/y) 2.1 1.57 2.04 1.11 1.53 1.27 1.6 0.8
Major bleeding (%/y) 3.6 2.75 1.61 3.11 2.71 2.13 1.4 2.1
gastrointestinal site (%/y) 3.2 1.51 0.82 1.51 1.12 0.76 0.4 0.9
Fatal bleeding (n) 27 32 21 n.a n.a 34 4 12
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o.d if Cr Cl was 30-50 ml, weight ≤ 60 kg or simultaneous 
use of the P-glycoprotein inhibitors verapamil or quini-
dine, and 7,034 patients to a treatment with “low-dose” 
edobaxan 30 mg o.d., reduced to a protocol mandated 
dose of 15 mg o.d. in the same circumstances as in the 
high-dose group. The reduced dose was given to 25.3% 
of the patients. The mean CHADS2 score was 2.8. Stroke 
or SE occurred in 1.57%/y of the patients on high-dose 
edoxaban, and 2.04%/y of the patients on a low dose. The 
rate of major bleeding was 2.75/y, 1.51%/y from gastro-
intestinal origin in the high-dose edoxaban group. The 
bleeding was fatal in 32 patients. In the group treated with 
low-dose edoxaban, the rate of major bleeding was 
1.61%/y. The origin was gastrointestinal in 1.19%/y of the 
patients, and in 21 patients the bleeding was fatal.
XANTUS15 is a real-world prospective observational 
study of patients with AF treated with rivaroxaban. In 
this study, 6,784 patients newly started on rivaroxaban 
were followed up at 3 months intervals for 1 year or for 
at least 30 days after permanent discontinuation of the 
drug. The mean CHADS2 score was 2 and all events were 
adjudicated by an independent central adjudication 
committee. The rate of stroke or SE was 0.8%/y. The rate 
of major bleeding was 2.1%/y. The origin of the bleeding 
was gastrointestinal in 0.9%/y of the patients, and the 
bleeding was fatal in 12 patients.
Comparison between studies
A fairly good relationship was observed between the 
CHADS2 risk score and the rate of stroke or SE (figure 1) 
and the rate of major bleeding (figure 2) in the different 
studies, with a clear difference in outcomes between the 
high and low dose of dabigatran in the RELY study and 
between the high and low dose of edoxaban in the 
ENGAGE-AF study, as could be anticipated. Somewhat 
of a surprise were the results with apixaban in the AVER-
ROES study, where the rate of stroke or SE was higher 
than expected from the CHADS2 score, but with a lower 
than expected rate of major bleeding. In the Engage AF 
trial, the rate of stroke or SE was 29% higher in the “low-
dose” group compared to the group of patients treated 
with 60 mg o.d., but in the “high-dose” group was a 70% 
higher rate of major bleeding.
In the RE-LY study, the rate of stroke or SE was 37% 
higher for the patients treated with dabigatran 110 mg 
b.i.d. compared to those treated with 150 mg b.i.d. but 
the rate of major bleeding was 18% higher in the group 
receiving dabigatran 150 mg b.i.d. In the AVERROES 
trial the rate of stroke was 27% higher compared to that 
in the ARISTOTLE trial, but in the latter the rate of 
major bleeding was 50% higher compared to the former 
trial despite an identical dosing protocol with apixaban 
5 mg b.i.d. (figure 3).
and major bleeding in 3.11%/y. The bleeding site was 
gastrointestinal in 1.51%/y of the patients. The CHADS2 
score in these patients was 2.2. The rate of stroke or SE 
in the 110-mg group was 1.53%/y and the rate of major 
bleeding 2.71%/y. The bleeding site was gastrointestinal 
in 1.21%/y of the patients. The CHADS2 score was 2.1. 
Data on fatal bleeding was not available.
Rivaroxaban is a factor Xa inhibitor evaluated in the 
phase III ROCKET-AF (The Rivaroxaban Once Daily 
Oral Direct Factor Xa Inhibition Compared with Vita-
min K Antagonism for Prevention of Stroke and Embo-
lism Trial in Atrial Fibrillation) study11. This trial rand-
omized 7,111 patients with AF to a treatment with 
rivaroxaban 20 mg once daily (o.d), or a protocol man-
dated dose of 15 mg o.d. if creatinine clearance (CrCl) 
was 30-49 ml/min (21% of the patients). The mean 
CHADS2 score was 3.5. Stroke or SE occurred at a rate 
of 2.1%/y. The rate of major bleeding was 3.6%/y. The 
site of major bleeding was gastrointestinal in 3.2%/y of 
the patients. The bleeding was fatal in 27 patients.
Apixaban, a second direct factor Xa inhibitor, was 
evaluated in two large phase III randomized controlled 
trials. In the ARISTOTLE (Apixaban for reduction in 
Stroke and other thromboembolic events in Atrial Fibril-
lation) study12, apixaban was compared with warfarin 
in a non-inferiority protocol. A total of 9,120 patients 
with AF were randomized to a treatment with apixaban 
5 mg twice daily or a protocol mandated dose of 2.5 mg 
twice daily in patients with two or more of the following 
criteria: age of at least 80 years, body weight of no more 
than 60 kg or a serum creatinine level of 1.5 mg/dL (4.7% 
of the total). The mean CHADS2 score was 2.1. Stroke 
or SE occurred in 1.27%/y of the patients. The rate of 
major bleeding was 2.13%/y. The site of bleeding was 
gastrointestinal in 0.76%/y of the patients. The bleeding 
was fatal in 34 patients.
In the AVERROES (Apixaban versus Acetylsalicylic 
Acid in Patients who have Failed or are Unsuitable for 
vitamin K antagonist) study13, apixaban was compared 
to aspirin in a superiority protocol. A total of 
2,808 patients were randomized to a dose of apixaban 
5 mg b.i.d or using the same criteria as in the ARISTO-
TLE trial to 2.5 mg b.i.d (6% of the total). The mean 
CHADS2 score was 2. Strokes or SE occurred in 1.6%/y, 
the rate of major bleeding was 1.4%/y and the site of 
bleeding was gastrointestinal in 0.4%/y of the patients. 
The bleeding was fatal in four patients.
Edobaxan, a third factor Xa inhibitor, was evaluated 
in the phase III ENGAGE AF-TIMI 48 (Effective antico-
agulation with Factor Xa next generation in Atrial Fibril-
lation-Thrombolysis in Myocardial Infarction 48 study) 
study14. In the ENGAGE AF trial, 7,035 patients with AF 
were randomized to a treatment with “high-dose” edo-
baxan 60 mg o.d., reduced to protocol mandated 30 mg 
W. Van Mieghem et al.4




%/y Major bleeding 
Fig. 1 Rate of stroke or 
SE (upper half ) and 
CHADS2 score (lower 
half ) in the various 
studies
Ro (Rocket AF: 
rivaroxaban 20 mg o.d.), 
En (Engage AF: edoxaban 
60 mg and 30 mg o.d.), 
Re (Rely: dabigatran 
150 mg and 110 mg 
b.i.d.), Ar (Aristotle: 
apixaban 5 mg b.i.d.), 
Av (Averroes: Apixaban 
5 mg b.i.d.), Xa (Xantus: 
rivaroxaban 20 mg o.d.).
Fig. 2 Rate of major 
bleeding, %/year (upper 
half ) and CHADS2) score 
(lower half ) in the 
different studies
Ro (Rocket AF: 
rivaroxaban 20 mg o.d.), 
En (Engage AF: edoxaban 
60 mg and 30 mg o.d.), 
Re (Rely: dabigatran 
150 mg and 110 mg 
b.i.d.), Ar (Aristotle: 
apixaban 5 mg b.i.d.), 
Av (Averroes: apixaban 
5 mg b.i.d.), Xa (Xantus: 
rivaroxaban 20 mg o.d.).
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in most studies. The lower bleeding rate with low-dose 
edoxaban in the ENGAGE AF trial and the lower dose of 
dabigatran in the RE-LY trial, compared to the higher 
doses, is expected, and a reflection of the lesser antico-
agulant activity at a lower dose. This clear impact on the 
rate of stroke and SE and the rate of major bleeding in the 
same risk category (CHADS2 score) of a higher or lower 
dose of the NOAC prescribed, allows the doctor and the 
patient to discuss the relative benefit (prevention of stroke 
or SE) and risk (major bleeding) of each treatment option 
related to the patient’s CHADS2 score, particularly relevant 
in cases with a higher CHADS2 score, where a choice can 
be made for a substantially higher risk of stroke or SE with 
a lower risk of major bleeding, or the opposite. Again, the 
difference in the rate of major bleeding between the ARIS-
TOTLE and AVERROES trials is also hard to elucidate 
(figure 3). 
The good relationship of the CHADS2 score and the 
rate of major bleeding in AF patients treated with 
NOACs is not unexpected. HAS-BLED16, the bleeding 
risk score derived from the EUROHEART survey, is an 
acronym for its constituting components: hypertension, 
The site of major bleeding was gastrointestinal in 35% 
to 55% of the bleedings in the different studies, with the 
exception of the ROCKET AF study with a gastrointes-
tinal origin of the major bleeding in 90% of the events. 
The mortality of the major bleedings was uniformly very 
low in all studies.
DISCUSSION
The CHADS2 risk score appears to be a reliable tool to 
predict the residual risk of stroke or SE for patients with 
AF treated with NOACs. These findings were consistent 
in the trials analysed except for the AVERROES study. 
The difference in the rate of stroke or SE between the high 
and low dose of the drugs for the patients in the ENGAGE 
AF and RE-LY trials is consistent with a greater antico-
agulant activity of the higher doses. The higher rate of 
stroke in the AVERROES trial compared to the ARISTO-
TLE (or XANTUS) trial is hard to explain (figure 3). 
A good continuous relationship was also found 
between the CHADS2 score and the rate of major  bleeding 
 




Fig. 3 Rate of stroke or 
SE (upper half ) and major 
bleeding (lower half ) in 
Engage AF, RE-LY, 
Aristotle and Averroes
En (Engage AF – 
edobaxan 60 mg and 
30 mg o.d.), Re (RE-LY 
– dabigatran 150 mg and 
110 mg b.i.d ), 
Ar (Aristotle – apixaban 
5 mg b.i.d), Av (Averroes 
– apixaban 5 mg b.i.d).
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the bleeding episodes unusual since there was no specific 
antidote for the NOACs available at that time and even 
without anticoagulant therapy is an acute gastric bleed-
ing associated with an expected mortality of 7%20.
LIMITATIONS
This paper is certainly not a comparison between the 
different studies with the NOACs but an evaluation of 
the possible association between the CHADS2 risk score 
and the rate of stroke or SE, and the rate of major bleed-
ing in patients with AF treated with one of the NOACs. 
The inclusion of a large high-quality prospective regis-
try, reflecting daily clinical practice, would certainly give 
additional values to the present hypothesis.
CONCLUSION
The CHADS2 risk score might be used to predict the 
risk of stroke or SE and the risk of major bleeding in 
patients with AF treated with a NOAC. Good adherence 
to the therapy is essential and the dose of NOAC has a 
large impact, with a lower rate of stroke or SE on a higher 
dose at the price of a higher rate of major bleeding. The 
mortality of major bleeding episodes was consistently 
low in the different studies despite the wide variety in 
bleeding sites. In patients with AF treated with NOACs, 
the CHADS2 risk score and the dose prescribed are thus 
likely more important to predict the occurrence of stroke 
or SE and the rate of major bleeding than possible dif-
ferences in the molecule of the different NOACs. 
CONFLICT OF INTEREST: none. 
abnormal liver/renal function, stroke, bleeding, history 
of predisposition, labile INR, elderly (> 65 y), drugs/
alcohol concomitantly. Per definition, the HAS-BLED 
score contains several components (hypertension, 
stroke, age) present in the CHADS2 score as well. Fur-
thermore, labile INR is not relevant in patients treated 
with NOACs. 
A similar relationship, as in the aforementioned stud-
ies reporting the relationship between the CHADS2 risk 
score and the rate of major bleeding, was also described 
in a recent analysis of the large database of the United 
States Department of Defense concerning electronic 
medical records of 27,467 patients with AF treated with 
rivaroxaban between February 1, 2013 and March 31, 
2014 17. The mean CHADS2 score was 2.2 and 496 major 
bleeding events were recorded in 478 patients, a rate of 
2.86% per person years. In the group of patients with 
major bleeding, the mean CHADS2 score was 3. 
The site of major bleeding was most commonly gas-
trointestinal (88.5%) and the bleeding mortality was very 
low (14 patients or 0.08% per 100 person years). Similar 
results were also observed in real-world and daily prac-
tice analysis concerning dabigatran with a rate of stroke 
or SE associated with the mean CHADS2 score values18,19.
The constantly good predictive value of the CHADS2 
score for the rate of major bleeding is, on the other hand, 
somewhat of a surprise since the definition and the site 
of major bleeding was not the same in the various stud-
ies. The number of patients who died because of bleed-
ing was low in every study despite the great variability 
in bleeding sites. The major bleedings were gastrointes-
tinal in 35 to 55% of the bleedings, with an exception in 
the ROCKET AF trial, where 90% of the major bleedings 
were gastrointestinal, and in the U.S. army database with 
a gastrointestinal origin of the bleeding in 88% of the 
bleeding events. This also makes the low mortality of 
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